142 related articles for article (PubMed ID: 17465232)
1. Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer.
Gormus U; Ergen A; Yilmaz H; Dalan B; Berkman S; Isbir T
Anticancer Res; 2007; 27(2):991-4. PubMed ID: 17465232
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma.
Zhou RM; Wang N; Chen ZF; Duan YN; Sun DL; Li Y
J Gastroenterol Hepatol; 2010 Mar; 25(3):555-61. PubMed ID: 20074157
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions.
Hsu PI; Lu PJ; Wang EM; Ger LP; Lo GH; Tsay FW; Chen TA; Yang HB; Chen HC; Lin WS; Lai KH
Anticancer Res; 2008; 28(1A):97-103. PubMed ID: 18383830
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma.
Cao Y; Miao XP; Huang MY; Deng L; Lin DX; Zeng YX; Shao JY
Mol Carcinog; 2010 Nov; 49(11):944-50. PubMed ID: 20842669
[TBL] [Abstract][Full Text] [Related]
5. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
Zhang B; Sun T; Xue L; Han X; Zhang B; Lu N; Shi Y; Tan W; Zhou Y; Zhao D; Zhang X; Guo Y; Lin D
Carcinogenesis; 2007 May; 28(5):1067-73. PubMed ID: 17183065
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
[TBL] [Abstract][Full Text] [Related]
7. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer.
Sun T; Zhou Y; Li H; Han X; Shi Y; Wang L; Miao X; Tan W; Zhao D; Zhang X; Guo Y; Lin D
J Exp Med; 2005 Oct; 202(7):967-74. PubMed ID: 16186185
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population.
Wang LH; Ting SC; Chen CH; Tsai CC; Lung O; Liu TC; Lee CW; Wang YY; Tsai CL; Lin YC
J Oral Pathol Med; 2010 Feb; 39(2):155-61. PubMed ID: 20359312
[TBL] [Abstract][Full Text] [Related]
9. Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection.
Jung YJ; Kim YJ; Kim LH; Lee SO; Park BL; Shin HD; Lee HS
Intervirology; 2007; 50(5):369-76. PubMed ID: 17938571
[TBL] [Abstract][Full Text] [Related]
10. [Association of three single nucleotide polymorphisms of the E-cadherin gene with susceptibility to epithelial ovarian carcinoma].
Liang J; Li Y; Wang N
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr; 25(2):183-6. PubMed ID: 18393242
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of IL-1A, IL-1B, IL-1RN, NFKB1, FAS, and FASL, and risk of silicosis in a Chinese occupational population.
Wu F; Xia Z; Qu Y; Tang Y; Cao D; Sun P; Christiani DC
Am J Ind Med; 2008 Nov; 51(11):843-51. PubMed ID: 18666137
[TBL] [Abstract][Full Text] [Related]
12. Functional variants in cell death pathway genes and risk of pancreatic cancer.
Yang M; Sun T; Wang L; Yu D; Zhang X; Miao X; Liu J; Zhao D; Li H; Tan W; Lin D
Clin Cancer Res; 2008 May; 14(10):3230-6. PubMed ID: 18483392
[TBL] [Abstract][Full Text] [Related]
13. Fas/FasL promoter gene polymorphism in patients with rheumatoid arthritis.
Kobak Ş; Berdeli A
Reumatismo; 2012 Dec; 64(6):374-9. PubMed ID: 23285481
[TBL] [Abstract][Full Text] [Related]
14. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer.
Lima L; Ferreira JA; Tavares A; Oliveira D; Morais A; Videira PA; Medeiros R; Santos L
Urol Oncol; 2014 Jan; 32(1):44.e1-7. PubMed ID: 23948181
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR.
Das H; Koizumi T; Sugimoto T; Chakraborty S; Ichimura T; Hasegawa K; Nishimura R
Br J Cancer; 2000 May; 82(10):1682-8. PubMed ID: 10817504
[TBL] [Abstract][Full Text] [Related]
16. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
Sung WW; Wang YC; Cheng YW; Lee MC; Yeh KT; Wang L; Wang J; Chen CY; Lee H
Clin Cancer Res; 2011 Sep; 17(18):5991-9. PubMed ID: 21807637
[TBL] [Abstract][Full Text] [Related]
17. Study of Fas (CD95) and FasL (CD178) polymorphisms in liver transplant recipients.
Marín LA; Muro M; Moya-Quiles MR; Miras M; Minguela A; Bermejo J; Sanchez-Bueno F; Parrilla P; Alvarez-López MR
Tissue Antigens; 2006 Feb; 67(2):117-26. PubMed ID: 16441482
[TBL] [Abstract][Full Text] [Related]
18. Fas and Fas ligand gene polymorphisms in primary Sjögren's syndrome.
Bolstad AI; Wargelius A; Nakken B; Haga HJ; Jonsson R
J Rheumatol; 2000 Oct; 27(10):2397-405. PubMed ID: 11036836
[TBL] [Abstract][Full Text] [Related]
19. Functional genetic variants in apoptosis-associated FAS and FASL genes and risk of bladder cancer in a Turkish population.
Verim L; Timirci-Kahraman O; Akbulut H; Akbas A; Ozturk T; Turan S; Yaylim I; Ergen A; Ozturk O; Isbir T
In Vivo; 2014; 28(3):397-402. PubMed ID: 24815844
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes.
Li Y; Hao YL; Kang S; Zhou RM; Wang N; Qi BL
Gynecol Oncol; 2013 Mar; 128(3):584-9. PubMed ID: 23234803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
